Genmab A/S to Discuss Proposed Acquisition of Call Transcript - Thomson StreetEvents

Genmab A/S to Discuss Proposed Acquisition of Call Transcript

Genmab A/S to Discuss Proposed Acquisition of Call Transcript - Thomson StreetEvents
Genmab A/S to Discuss Proposed Acquisition of Call Transcript
Published Apr 03, 2024
18 pages (11198 words) — Published Apr 03, 2024
Price US$ 54.00  |  Buy this Report Now

About This Report

  
Abstract:

Edited Transcript of GMAB.CO M&A conference call or presentation 3-Apr-24 11:00am GMT

  
Brief Excerpt:

...Hello, and welcome to today's conference call to discuss Genmab's acquisition of ProfoundBio, an event that excellently aligns with our long-term strategy and our ambitious 2030 vision. With me today to present this exciting news, our Chief Medical Officer, Tahi Ahmadi; and our CFO, Anthony Pagano. For the Q&A, we will be joined by Genmab's Chief Development Officer, Judith Klimovsky; and Chief Operating Officer, Anthony Mancini. Before we continue, just a reminder that we will be making forward-looking statements, so please keep that in mind as we go through the rest of this call. We are fully committed to evolving Genmab into a leading fully integrated biotech innovation powerhouse. And we are doing it by...

  
Report Type:

Transcript

Source:
Thomson StreetEvents
Company:
Genmab A/S
Ticker
GMAB.CO
Time
11:00am GMT
Format:
PDF Adobe Acrobat
Buy Now

The following is excerpted from the question-and-answer section of the transcript.

(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)

Question: Xian Deng - UBS Investment Bank, Research Division - Analyst : Two, please. The first one is, you mentioned several times that drug antibody ratio of 8, which is actually quite high. But yes, the safety data so far looks quite good. I mean you already kind of touched on it, but just wondering if you could elaborate a little bit what do you think is -- the reason for this, do you think is the half life of the payload or specificity role of the antibody or the linker, et cetera, or something else? And then the second question is kind of a follow-up on the Jonathan's question is that is there any data that you could possibly share today on non-ovarian and endometrial cancer?

Table Of Contents

Genmab A/S Virtual R&D Update and ASH Data Review Transcript – 2024-12-11 – US$ 54.00 – Edited Transcript of GMAB.CO corporate analyst meeting</ 11-Dec-24 4:00pm GMT

Genmab A/S at Citi Global Healthcare Conference Transcript – 2024-12-03 – US$ 54.00 – Edited Transcript of GMAB.CO presentation 3-Dec-24 7:30pm GMT

Genmab A/S Q3 2024 Earnings Call Transcript – 2024-11-06 – US$ 54.00 – Edited Transcript of GMAB.CO earnings conference call or presentation 6-Nov-24 5:00pm GMT

Genmab A/S at Morgan Stanley Global Healthcare Conference Transcript – 2024-09-04 – US$ 54.00 – Edited Transcript of GMAB.CO presentation 4-Sep-24 5:05pm GMT

Genmab A/S Q2 2024 Earnings Call Transcript – 2024-08-08 – US$ 54.00 – Edited Transcript of GMAB.CO earnings conference call or presentation 8-Aug-24 4:00pm GMT

Genmab A/S Q3 2023 Earnings Call Transcript – 2023-11-07 – US$ 54.00 – Edited Transcript of GMAB.CO earnings conference call or presentation 7-Nov-23 5:00pm GMT

Genmab A/S at Morgan Stanley Global Healthcare Conference Transcript – 2023-09-12 – US$ 54.00 – Edited Transcript of GMAB.CO presentation 12-Sep-23 7:35pm GMT

Half Year 2023 Genmab A/S Earnings Call Transcript – 2023-08-03 – US$ 54.00 – Edited Transcript of GMAB.CO earnings conference call or presentation 3-Aug-23 4:00pm GMT

Genmab A/S at Goldman Sachs Healthcare Conference Transcript – 2023-06-13 – US$ 54.00 – Edited Transcript of GMAB.CO presentation 13-Jun-23 6:20pm GMT

Genmab A/S Q1 2023 Earnings Call Transcript – 2023-05-10 – US$ 54.00 – Edited Transcript of GMAB.CO earnings conference call or presentation 10-May-23 4:00pm GMT

More from Thomson StreetEvents

Thomson StreetEvents—Thomson StreetEvents is a leading provider of Web-based solutions for the investment community, offering services that transform the way companies communicate and meet disclosure requirements while assisting investors in managing and leveraging this information. Thomson StreetEvents service offers institutional investors a one-stop solution for managing corporate disclosure information by aggregating conference calls, webcasts, transcripts, call summaries, and other financial information into a time-saving, efficiency tool.
Purchase Thomson StreetEvents' Transcripts (verbatim reports) and Briefs (call summaries) of earnings, guidance, M&A and other corporate calls directly through Alacra. Discounted prices apply to reports produced over two weeks ago.

About the Author


Cite this Report

  
MLA:
Thomson StreetEvents. "Genmab A/S to Discuss Proposed Acquisition of Call Transcript" Apr 03, 2024. Alacra Store. Nov 06, 2026. <http://www.alacrastore.com/thomson-streetevents-transcripts/Genmab-A-S-to-Discuss-Proposed-Acquisition-of-Call-T15942400>
  
APA:
Thomson StreetEvents. (2024). Genmab A/S to Discuss Proposed Acquisition of Call Transcript Apr 03, 2024. New York, NY: Alacra Store. Retrieved Nov 06, 2026 from <http://www.alacrastore.com/thomson-streetevents-transcripts/Genmab-A-S-to-Discuss-Proposed-Acquisition-of-Call-T15942400>
  
US$ 54.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Credit Research from one place.